---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-297163"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2022-12-02T23:59:59+00:00"
generated_at: "2026-06-21T10:16:46.722490+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics reports 55% reduction in convulsive seizures in Phase 1/2a study of STK-001 in Dravet syndrome

## Summary
- 55% median reduction in convulsive seizure frequency from baseline in 6 patients treated with three doses of 45mg STK-001.
- 5/6 (83%) patients showed reductions; 4/6 (67%) had >50% reduction from baseline.
- STK-001 up to 45mg well-tolerated; 27% (15/55) of patients had treatment-related AEs, all mild/moderate, no withdrawals.
- Reductions in seizure frequency maintained in SWALLOWTAIL open-label extension; trend toward improvement in executive function (BRIEF-P).
- One-year BUTTERFLY observational data showed little change in cognition without STK-001 treatment, highlighting disease progression.

## SEC filing metadata
- accession: 0001193125-22-297163
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2022-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/0001193125-22-297163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312522297163/d428421d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-297163
- JSON: https://secwatch.observer/filing/0001193125-22-297163.json
- Plain text: https://secwatch.observer/filing/0001193125-22-297163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.